The Indianapolis Star from Indianapolis, Indiana • Page 34

I I I C10 THE INDIANAPOLIS STAR TUESDAY, MAY 7, 1996 '91 Lola lives to run another day Scandia pairs up Italians Alboreto and Zampedri Drinan's machine once raced in the mud at Pike's Peak. Just after practice ended Monday at the Indianapolis Motor Speedway, Dan Drlnan left for a Downtown autograph party with many of his fellow drivers. to pass his rookie test. Carlson Is a team member whose father's company, State Bail Bonding, is one of the two sponsors (Kelly's Pub Too is the other). For spare parts, the team has two extra motors, gearbox replacements and some front suspension pieces.

That's It. 'The car has a pretty amazing history, doesn't it?" Bud Hoffpauir said. Goodyear better by the day Scott Goodyear, who still wears a back brace following his accident at Brazil, will see Dr. Terry Trammell in the coming days to receive clearance to return, likely at Detroit. "I've reached that phase that Trammell warned me about, when I feel better but I need to be careful not to do too much," he said.

Notes Mark Dismore needed 71 minutes to pass his rookie test, the best of the '96 class to date. The record (since '81) is held by Nigel Mansell (52 minutes in '93) for the Indianapolis 500 is worth $5,000 to the team that most overachieves. "If we make the race," Mike Smith said, "we're a shoo-in." The Hoffpaulrs not only have the only 1991 chassis on the entry list, they have the only car that has raced Pike's Peak in the mud no less. They bought the car from Leader Card some 18 months ago for $35,000, a price that was $10,000 more than It had been the year before. The Hoffpauirs ran Buddy Lazier roughly 2,500 miles at a track in Pueblo, and made the Lola a three-time winner on the American Indycar Series.

The car's debut was the '91 Indianapolis 500, where Danny Sullivan finished 10th with Alfa Romeo power. Lazier finished 14th in it in '92 but missed the '93 show when the engine broke in qualifying on the final day. Now powered by a Buick and a veteran of an estimated 15,000 miles, the car is expected to be available today for Tyce Carlson Alboreto joined Ferrari In 1984 and drove five years for the Flying Horse marque out of Modena. Zampedri, meanwhile, began his career in 1988 competing in the Italian Formula Boxer championship, winning the title In 1989. He moved on through Formula 3 and Formula 3000 before making his Indy-car debut in 1994 in a Dale Coyne car.

Last May as an Indy 500 rookie, he was the first driver on the track and qualified at 225.753 mph in a Coyne-Walter Payton car. Eventually, he started 17th and ran as high as ninth before settling for 11th. So, is Zampedri prepared to give his more illustrious stablemate some advice on how to drive the Speedway? "No," he replied with grin. "He's not the kind of guy who asks for your advice." The Mi-Jack sponsorship could have stayed with Coyne-Payton in CART, but Lanigan chose to return to Indy. Zampedri called the arrangement a very good opportunity.

"I think with Andy Evans and Dick Simon, I will have a very good car," he said. "It will have a good setup." By Dick Mittman STAFF WRITER In 1985, Michele Alboreto was a hero across Italy driving the flaming red Ferrari in Formula One. Alessandro Zampedri, a 14-year-old driving go-karts, was one of Alboreto's fanatic countrymen who idolized him. Fast forward to May 1996. Alboreto, his F-l career 194 races and five victories behind him, has ventured to America and an Indy Racing League ride with Scandia Racing.

He's at the Speedway as a rookie driving an Andy Evans-owned 1995 ReynardFord Cosworth. Monday, Alboreto, 39, got a new teammate: 26-year-old Alessandro Zampedri. Since he drove to 11th in last year's Indianapolis 500, Zampedri now is the veteran in the garage. "It's a very funny feeling," said Zampedri, who closed a deal with Lanco Group (Mi-Jack) president Mike Lanigan. "(Michele) was a hero of everybody in Italy.

Italians have the power to make you a hero in a day and destroy you in a dayi The fact is, I'm now here and we're teammates. It's nice." Pit Pass remained in the Curt Cavin garage of Loop Hole Racing, where Bud and Dan Hoffpauir spent the early evening working on the race car Drinan drove for nearly 228 miles in the first full day of USAC's Rookie Orientation Program. That their car had only a small shock problem over those 91 laps top speed of 210.694 mph (eighth quick of 16) is a testament to accomplishing a lot with a little. In fact, crew members noted that a contingency award Photo Steve Noreyko LUNCH BREAK: Buzz Calkins grabs a bite to eat along the pit wall Monday. Bob Lutz, Chrysler's president, will be the honorary pace car driver A pair of car owners are close to naming second drivers for the U.S.

500 at Michigan. Best bets: Gary Bettenhausen for Tony Bettenhausen and Fredrlk Ekb-lom for Derrick Walker wwiw STEWART Continued from Page 1 ft i I i 1 I. 4 MONDAY'S TOP SPEEDS Car Driver MPH 20 Tony Stewart 237.336 32 Tony Stewart 230.438 30 Mark Dismore 228.566 22 Michel Jourdain 228.154 12 Buzz Calkins 227.411 44 Richie Hearn 226.592 33 Michele Alboreto 226.415 23 Mark Dismore 222.283 93 Racin Gardner 211.159 36 Dan Drinan 210.694 27 Jim Guthrie 209.996 10 Brad Murphey 209.035 45 Randy Tolsma 208.923 96 PaulDurant 197.707 64 Johnny Unser 195.627 25 JoeGosek 189.143 43 Fermin Velez 188.992 15 Justin Bell 171.389 SPEED CHART H) i 1 QlxluJi Iftillllifc comparisons. "I thought something was wrong because Larry (Cufry, team manager) was screaming on the radio, 'Pit, I radioed back and wanted to know what was wrong. He said, 'Nothing, you were real The 24-year-old resident of Rushville, who in 1995 became the first driver to win three USAC titles in the same season, warmed up at 231 mph during the final phase of his rookie test.

"Honestly, I told Larry it was more comfortable at 237 than it was at 231," said Stewart, who debuted with a second in the Indy Racing League opener at Orlando. "All we did was change the setup, change engines and trim the car out a little more. "And all I did was push it (throttle) down and hold it down until he (Curry) called me in." Curry, who convinced owner John Menard to hire Stewart, was asked about a speed ceiling. "People ask me if 240 Is a possibility and the guy sitting next to me (Stewart) thinks there's more left in the car, so we'll see," he replied. "I kept him on a short leash through testing, but he'd already run 235 in similiar conditions." Stewart said: "The car is comfortable where it is right now and I don't know where my limits are yet.

Larry keeps pushing me and has given me the confidence to go that quick. Scott (Brayton) whipped his lap out on a pretty windy day so he might be able to go a little better." Brayton, Luyendyk and the rest of the veterans will begin practicing this morning at 11 following two more hours of rookie orientation. But Monday belonged to the newcomers as Mark Dismore, Michel Jourdain, Buzz Calkins, Richie Hearn, Michele Alboreto, Ra-cin Gardner, Dan Drinan, Jim Guthrie, Brad Murphey and Randy Tolsma joined Stewart in passing the rookie test. It was a nice return for Dismore, who survived a bad accident here in 1991 but is finally back with a good ride. "ROP (rookie orientation) went Take SPORANOX treatment orally for just 3 months and you may see a visible difference.

Soon after you stop taking SPORANOX, you may notice that the new nail growing in appears normal. Since nails need time to grow, you should expect it to be several months before healthy, new nails grow in. So, now you can give thick, yellowing, brittle nails the boot and start growing fresh, new nails! Ask your doctor or other healthcare professional about prescribing SPORANOX today. For more information, call Sec MPH Sec MPH 45.0 200.00 41.1 218.98 44.9 200.44 41.0 219.51 44.8 200.89 40.9 220.05 44.7 201.34 40.8 220.59 44.6 201.79 40.7.... 221.13.

44.5 202.24 40.6 221.67 44.4 202.70. 40.5 222.22.; 44.3. 203.16 40.4 222.77 44.2 203.62 40.3 223.22. 44.1 204.08 40.2 223.88 44.0 204.54 40.1 224.44 43.9 205.01 40.0 225.00 43.8 205.47 39.9 225.56 43.7 205.95 39.8 226.13" 43.6 206.42 39.7 226.70' 43.5 206.89 39.6 227.27' 43.4 207.37 39.5 227.85 43.3 207.85 39.4 228.43 43.2 208.33 39.3 229.01 43.1 208.81 39.2 229.59, 43.0 209.30 39.1 230.18 42.9 209.79 39.0 230.77, 42.8 210.28 38.9 231.36- 42.7 210.77 38.8 231.96 42.6 211.27 38.7 232.56 42.5. 211.77 38.6 233.16" 42.4 212.26 38.5 233.77 42.3 212.77 38.4 234.38.

42.2 213.27 38.3 234.99 42.1 213.78 38.2 235.60 42.0 214.29 38.1 236.22 41.9 214.79 38.0 236.84, 41.8 215.31 37.9 237.47 41.7 215.83 37.8 238.10 41.6 216.35 37.7 238.73' 41.5 216.87 37.6 239.36 41.4 217.32 37.5 240.00 41.3 217.92 37.4 240.64 41.2 218.45 37.3 241. 29 A What you should know about the safety of SPORANOX: SPORANOX has been well tolerated in patients. In clinical trials involving patients with thick, hard, yellowish, andor brittle nails (onychomycosis), the following adverse effects led to either a temporary or a permanent discontinuation of treatment: elevated liver enzymes (4), gastrointestinal disorders (4), and rash (3). WARNING: SPORANOX must not be taken with terfenadine (Seldane), astemizole (Hismanal8), cisapride (Propulsid), or oral triazolam (Halcion). In rare instances, there were reports of elevated liver enzymes and hepatitis.

(If clinical signs and symptoms consistent with liver disease develop, SPORANOX should be discontinued.) If you're pregnant or considering pregnancy, you should not take SPORANOX. Take SPORANOX only as directed by your doctor, and report any adverse effects to your doctor as soon as possible. NOW 100 mg sporanoxr (itraconazole capsules PLEASE SEE IMPORTANT PRECAUTIONARY INFORMATION BELOW. mgkgday, showed that the pharmacokinetics of zidovudine were not affected during concomitant ADVERSE REACTIONS In US. clinical trials prior to marketiniL uSere have been uwcasesof reversible idiosvncratk heDatitis reoorted among more than 2500 patients.

One patient outside the US developed fulminant hepatitis and died during SPORANOX (itraconazole capsules) administration Because this pabent was on multiple medications, the WARNING Coadministration of tafenadme with itraconazole aontraincbcated. Sehoui cardiovascular aw events, induc death, vai taking itraconazole concomitantly with terfenadine. This is due to elevated terfenadine concentrations caused by itraconazole. See CONTRAINDICATIONS, WARNINGS, and PRGCALHIONSsectum Another oral azole antifungal ketoconazole, mtubtts the metabohsm of astemizole. resulting in elevated ptasmacoimtntioreofasteirazoleiridto intervals.

Based on results of an nr mtn study and the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole and itraconazole is contraindicated. See CONTRAINDICATK3NS. WARNINGS, and PRECAW0N5 sections. CWnrnustratui of cisapnde with itncoiuzoie is oontrzindkatedl. Serious ctrdiovasrular advene evcids including death, ventricular tachycardia, and torsades de pennies have occurred in patients taking itraconazole concomitantly with cisapride.

See CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS sections. ausai dHoaaaon wim aruiwAJA uncertain, see nuuNinij? section.) ONYCHOMYCOSIS; Adverse everts the Wkiwing tallied to ehlw temporary cr permanent di with such a first-class team," said the Greenfield native, who ran 228-plus in Menard's Quaker State '95 LolaMenard. "I haven't, been here in five years and this place is really special to me. "Driving a well-prepared car. makes such a difference." I modence() Body System Advene Event n112) Elevated Liver Enzymes (2x normal range) 41 Gastrointestinal Disorders 4 Rash 3 Hypertension 2 Orthostark HypcHenston Headache 1 Malaise Myalgia Vasculitis It Verogo STBCRMINrCTlONS Adverse experiencedata in dw following tabWarederived from 602 pabenls treated for systemic fungal disease in VS.

clinical trials, who were immurocOTnoromised or receiving multiple concomitant tnedkations. Of these patients, treatment was discontinued in 105 of patients due to adverse events. The median duration before chsoantinuabon of therapy was 81 days, with a range of 2-776 davs. The Uble lists adven events reported by at '25 win brings DePaolo out from the shadows WARNTNCvCCWTRAINDOTONS, and WARNINGS sections,) Human phannacoianetics data indicate mat oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapnde. Data suggest mat coadministration of oral ketoconazole and cisapride can result in prokmgation of theOT interval on the GCG.

in mttp data suggest that itraconazole also inarkedly inhibits the biotransfoftnation system mainly responsible for the metaboWn of cisapride; therefore concomitant administration of SPORANOX with cbapride is aintramdicated. (See BOX WARNING, OONTRAINDOTIONS, and WARNINGS sections.) Coadministration of SPORANOX with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs. The may potentiate and proline hypnotic and sedabve effects. These agents should not be used in pabents treated with SPORANOX. If midazolam is adiwrastered parententty, special preautmBreouirdsDxefe Cc4dmintstrabon of SPORANOX and cydosponne, tacrolimus or djgoxin has led to increased plasma concentrations of the latter three drugs.

Cydosponne, tacrolimus and digoan concentrations should be monitored at the imtubon of SK)RAN0X therapy and n-equently meinfter, and the doseof these three drug products adjusted appropriately. There have been rare reports of rhabdrmyofysis involving renal transplant patients receiving the combination of SPORANOX, cydosponne, and the HMG-CoA reductase inhibitors lovastatin or simvastatin. Rhabdomyolvsis has been observd recommended dosages) or concomitantly with inununosuppressve drugs including cyclosporin. When SPORANOX was coadministered with phenytoin, rifampin, or antagonists, reduced plesma concentrations of taaconazole were leported The physuan is advised to nwto itraconazole when any of these drugs is taken concurrently, and to increase the dose of SPORANOX if necessary. Although no studies have been conducted, concomitant administration of SPORANOX and pfowtommavaftethemetatoh monitored when it is given concurrently with SPORANOX.

It has been reported that SPORANOX enhances the anticoagulant effect of osumarin-Eke drugs. Therefore, prothrombin tune should be carefully monitored in pabents recaving SPORANOX and aximann-like drugs simultaneously. Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid. Itracona2ole plafana conexntrabons shotud be monitored when SPORANOX and isoruazi afecoaoruiustered. Severe hypoglycemia has been reported in pabents concomitantly receiving azole antifungal agents and oral hypogivcernic assents.

Mood glucose ooncsnbaaoitt should becarenilry monitored when SPORANOX and oral hypoglycemic agents aremadnuiustered. Tinnitus and decreased hearing have been reported in patients coftcomkantfy receiving SPORANOX and quuudine. Edema has been reported in patients concomitantly receiving SPORANOX and dihydrcyyndme calcium channel blockers. Appropriate doapadjustnients may be necessary. The results from a study in which eight HIV-infected individual were treated with zidovudine, 8 0.4 mgkgday, showed that the pharmacokinetics of zidovudine were not affected during concomitant aiWotsimNOXjLllmKbjd.

Gtrnncfffwsis, and tmpairml ffrlifify: Itraconazole showed no evidence of carcinogenicity potential in mice treated orally for 23 months at dosage levels up to 80 mgkgday approximately lOx the maximum recommended human dose (MRHD), Male rats treated with 25 mgkgday (3.1x MRHD) had a slightly increased incidence of soft tissue sarcoma. These sarcomas may have been a consequence of hypercholesterolemia, which is a response of rats, but not dogs or humans, to chronic itraconazole administration. Female rats treated with 50 mgkgday (6.25x MRHD) had an increased incidence of squamous cell carcinoma of the lung (250) as compared to the untreated group. Although the occurrence of squamous cell carcinoma the hmg is extremely uncommon in untreated rats, the increase this study was ndstatisacalrysignihanl Itraconazole produced no mutagenic effects when assayed in appropriate bacterial, non-mammalian and mammalian test systems Itraconazole did not affect the fertility of male or female rats treated orally with dosage levels of up to 40 mgkgday (5x MRHD) even though'parental toxicity was present at this dosage level. More severe signs of parental ttmdty, including death, were present in the next higher dosage level 160 mgkgday (20x MRHD), Teratogenic Effects.

Pregnancy Category Itraconazole was found to cause a dose-related increase maternal toxicity, embryotoxiaty and teratogenicity in rats at dosage levels of approximately 40-160 mgkgday (5-20x MRHD) and in mice at dosage levels of approximately SO mgkeday (10 MRHD). In rats, the teratogenicity consisted of maor skeletal defects; in mice it consisted of encephaloceles andor macroglossia There are no studies in pregnant women. SPORANOX should be used lor the treatment of systemic fungal infections in pregnancy only if the benefit outweighs the potential risk. SPORANOX should not be administered tor trie treatment of cmchomvrow to pregnant patients or to women contemplating pregnancy. SPORANOX should not be administered to women of child-bearing potential for the treatment of onycncmycc unless they are talun on the second or third day of the next normal rneratrual period.

Effectrve oontracepbon ahould be continued throughout SPORANOX therapy and for 2 monuw foUowing beatment. Itraconuole is excreted in human milk; bSerefore, SPORANOX should not be adrninistered to nursing women, Pfiftftric The efficacy and safety of SPORANOX have not been established in pediatric patients. No i phannacokuietic data are available chilc with lOOmgdayofitracnuztxeforsvsteinKf been reported. In three toxicology studies using rats, itraconazole induced bone defects at dosage levels as low as 20 mgkgday (25x MRHD). The induced defects included reduced tone piate activity, thmiung of the zona comparta of the large bones and iiweasedbcwfrag Atadosagelevri MRHD) over one year or 160 mgkgday (20x MRHD) for su months, itraconazole induced small tooth pulp with hyporellular appearance in some rats.

While no such bone toxxity has been patients, me long tenne patients is unknown. HiV-inffffflffotimfr Because hypochlorhydria has been reported in rflV-infeded individuals, the absorption of itraconazole in these patients may be decreased. The results fjon a study in which eight HIV-infected individuals were treated with zidovudine, ft 0.4 Body SystemAdvene Evait Inddence) Psydiiatnc Disorders libido decreased 2 Somnolence 1 Cardiovascular Disorders Hypertension Metabolic and Nutritional Disorders HyUemia 10 tlririary System Disorders Albuminuria 13 Liver and Biliary System Disorders Hepatyhmctwn abnormal 17 Reproductive Disorders, Male Impotence 2 Body System Adverse Event (Incidence? H) Incidence (S) Gastrointestinal Disorders Nausea 106 Vomiting 5,1 Diarrhea 33 Abdominal Pain 15 Anorexia 1.2 BodyasaWhole Edema 33 Fatigue Fever 25 Malaise Skin and Appendages Rash 8.6' Pruritus 25 Central and Peripheral Nervous System Headache Dizziness 1.7 Peter DePaolo had spent a number of years very much in the shadow of his famous uncle Ralph De-Palma, first serving as riding mechanic for DePalma's pole-winning efforts in 1920 and "21 and then leading the 1992 race as driv INDICATIONS AND USAGE SPORANOX (itraconazole capsules) is indicated lor the treatment of the following fungal infections in immuncompromised and immunocompromised patients: 1. Blastomycosis, pulmonary and exft pulmonary; hKoptlsmoa Ind diwmiMWd, non-meiungeal 1 Awjnlloas, pulmonary and extrapihnoiary, patienb amphotericin therapy; and 4. Onvchomvow due to dennatcf (bra CONTRAINDICATIONS Coadministration of terfenadine, astemizole or cisapride with SPORANOX (itraconazole capsules) is contramdicated.

(See BOX WARNING, WARNINGS, and PRECAUTIONS sections.) Concomitant adininistration of SPORANOX with oral triazolam or with oral midazolam is contraindicated. (See PRECAUTIONS section.) SPORANOX should not be administered for the b-eaAmentof onyiJumycoats to pregnant patients or to women contemplating pregnancy, SPORAiX arantnindicated in pabents who hanreshown bypnensitivity lo thedrug or iteexcipienls. There is no information regarding cross hvpmerativitv between itraconazole and other azole antifungal agents. Caution should be used prescribing 5K)RAN0Xto patients wtiihypenera WARNINGS InUSdiraaltrialsprw among more than 2500 patients taking SPORANOX (itraconazole capsules). One patient outside the US.

developed fulminant hepatitis and died during SPORANOX admmtstrabon. Smce this pabent was on muttipli? medications, the causal association with SK)RAN0X is uncertain. L' dinical signs and symptoms consistent with liver disease develop that may be attributable to itraconazole, SPORANOX should be discontinued. Prior to US. marketing, mere have been three cases of life-threatening cardiac dysrhythmias and one death reported in patients receiving terfenadine and itraconazole.

(See BOX WARNING, CONTRAINDICATIONS, artdrWALTONSsecDoni) Coadministration of astemizole with SPORANOX is contraindicated. (See BOX WARNING, OONTRAJNTJICATIONS, and rTulCAUTlCWSsections.) Concomitant admmistntion of oral ketoconazole with cisapride has resulted in marVedlv elevated cisapride plasma concentrabom, prolonged QT mtervak, and has rarefy been associated with ventricular nrhvthmias and torsades de parte Due to potent in nfro inhibition of the hepafcenzw the metabc asapnde (cytorhnme P4 plasma concentntiom; therefore, concomitant use of cisapnde with SPORANOX contraindicated, (See BOX WARNING, CCIMNDfCATIONS, and PRKAUT10NS sections.) PRECAUTIONS Gtnmi: Hepatic enzyme test values should be monitored in patients with preexisting hepatic function abnormalities. Hepatic enzyme test values should be monitored periodically in all patients receiving continuous treatment for more than one month or at any time a patient develops signs or symptoms suggestive of live dysfunction. SPORANOX btracrrtazcie capsules) shoiild be administered ateah Under fasted conditions, toaconazoleabsorptini was decreased mu absorption of itraconazole may be decreased with the concomitant administration of antacids or gastric acid secretion nippresson. Studies conducted under fasted conditions demonstrated that administration with 8 ounces of a cola beverage resulted increased absorption of itraconazole in AIDS patients with relative or absolute achlcchydria.

This inaease relative to dV effects o( a hiU meal is unlu Pabails should be instructed to report any stns and symptoms that may suggest bver dvfunctiori that the appropriate laboratory testing can be done Such signs and symptoms may include unusual fatigue, anorexia, nausea andor vominng, jaundice, Murine or piie stool. jntmctmp Both itraconazole and its major metabolite, hydrcnyitraconazole, are inhibitors of the cytochrome P450 3A4 enzyme system. Ojadnunistnition of SPORANOX and drugs primarily metabolized by thecytodiromeft3A4enzy increase or prolong both therapeutic and advene effects, Therefore, unless otherwise specified, appropriate dosage acfaistmenfe may be necessary. Ccflcbiuustration of terfenadine with SPORANOX has led to elevated plasma concentrations of terfenadine, resufertg ui nre nstances of lrfe-rirMrteninfl cardiac dysriiythmias and one cleatK (See BOX WARNING, CON-TRAJNMCATIONS, and WARNINGS sections) Another oral aioleantihinfl, keiocDiuzoie, inhibits theinetabolism of aurernizole, resullinB in eievatpd plasma concentrations of astemizokand its active metabolite desniethylastemizole which may prolong QT intervals. In wire data suggest that itraconazole, when compared to ketoconazole, has less pronounced effect on the bwtransfomutionsyre itraconazole and tetoc Donald Davidson's Indy 500 Rash tends to occur more frequently in immunocompromised patients receiving immunosuppressive UUUIMB.

Advene events infrequently reported in all studies induded: constipation, gastritis, depression, insomnia, a record 101.13 mph. Peter's month-of-May residence in those days was with the Hock-enschmidt family on West 15th Street in Speedway. He and his wife Sally left the garage area about 5 p.m. after the race, and walked across the track at the entrance to turn one and out of the main gate at the corner of West 16th Street and Georgetown Road. Feeling a little puny and estimating that he had lost about 11 pounds during the ordeal on the bricks, Peter set about replacing it on the corner of 16th and Main.

The DePaolos had stopped off at Rosner's drug store for a double chocolate malt. From there, they walked back to the Hockensch-midt's, where Sally ran a bath for her beaten-up husband. After soaking for a while and taking a shot of grape brandy, he began to feel a little better, the urge to sing a few of his favorite operatic arias finally overwhelming him, much to the delight pf the neighbors. i uEOTUCTty.jTTmoniasuina indKCfeastpun. mworuwxiepo6rmariexperienffwto anpoedema and in rare mstancis.

anaphylaxis and SteMjc4inson syTKbwne, have been reported. Marketing experiences have also included reports of elevated liver enzymes and rare herabtn Although the causal association with SPORANOX is uncertain, rare hypertriglyceridemia and isolated cases of neuropathy have OVERDOSAGE Itraconazole is not removed by dialysis. In the event of accidental overdosage, supportive measures, induding gastric lavage with sodium bicarbonate, shoukll employed No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage er himself before crashing. But in 1925, Peter was vindicated. He had become the number one driver for the Duesenberg team and was lined up on the front row in one of their new supercharged straight-eights.

He had to take 21 laps of relief from Norman Batten lasting about 35 minutes while his badly blistered hands were taped, but he finished ahead of the competition and was the first person to ever finish the rac( in under five hours. His winning speed was rveo joi uty ur uup aw nqj Kg. US. Patent No. 467,179 Rev.

ApnJ 1995, September 1995 7501606 world leader in antifungal research JANSSEN Tilusville, NJ 08560-0200 Janssm Pharmaceutics Inc. 1995 JPI-SP-104S November 1995rinled in U.S.A..